In this picture supplied by Eli Lilly, a scientist tests possible COVID-19 antibodies in a lab in Indianapolis, Ind. On Monday, U.S. federal government authorities revealed they are putting an early end to a research study checking an Eli Lilly antibody drug for individuals hospitalized with COVID-19 due to the fact that it is not likely to assist.

The trial studied the effectiveness of bamlanivimab in mix with the antiviral remdesivir on hospitalized COVID-19 clients. Scientist concluded the antibody treatment was “not likely to assist.”

(Image credit: David Morrison/AP)

Read more: npr.org

Related posts:

  1. Russia’s Covid-19 vaccine generated an immune response, study says
  2. Russia’s potential coronavirus vaccine shows ‘no serious adverse’ effects and creates antibody response: The Lancet study
  3. Google Secretly Collecting Data On Millions Of Americans, Not Telling Patients Or Doctors, Report Says
  4. Coronavirus vaccine trial participants report day-long exhaustion, fever and headaches — but say it’s worth it